Leonora R. Slatnick
No Rating Available
(Learn About Our Rating System)

Leonora R. Slatnick, MD, MSCS

Languages spoken: Spanish, English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

1950 Circle of Hope
Salt Lake City , UT 84112
801-587-4745
Get Directions

University Pediatric Clinic

University Pediatric Clinic
50 N Medical Dr
Salt Lake City , UT 84132
801-581-2205
Get Directions

Dr. Slatnick is currently an assistant professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. She is a member of the Solid Tumor team at the University of Utah and Primary Children’s Hospital. She received her medical degree from the University of Texas Southwestern Medical School.

She completed her pediatric residency in Pediatrics at the University of Colorado School of Medicine. She also completed her fellowship in Pediatric Hematology-Oncology and MSCS degree in Clinical Sciences at the University of Colorado.

Dr. Slatnick is board-certified by the American Board of Pediatrics and National Board of Medical Examiners. She is a member of many professional societies, including The American Academy of Pediatrics, Children's Oncology Group, The National Comprehensive Cancer Network (NCCN) Neuroblastoma Committee, The American Society of Clinical Oncology, The American Society of Hematology, and the Children’s Oncology Group. She has over 10 years of research experience.

Dr. Slatnick’s clinical interests include all solid tumors with a specific interest in neuroblastoma therapy. Her primary research focuses on supportive care practices in immunocompromised patients, with a particular interest in infectious complications and antimicrobial management in the oncology patient population.

Specialties

Board Certification

American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
National Board of Medical Examiners

Dr. Slatnick is currently an assistant professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. She is a member of the Solid Tumor team at the University of Utah and Primary Children’s Hospital. She received her medical degree from the University of Texas Southwestern Medical School.

She completed her pediatric residency in Pediatrics at the University of Colorado School of Medicine. She also completed her fellowship in Pediatric Hematology-Oncology and MSCS degree in Clinical Sciences at the University of Colorado.

Dr. Slatnick is board-certified by the American Board of Pediatrics and National Board of Medical Examiners. She is a member of many professional societies, including The American Academy of Pediatrics, Children's Oncology Group, The National Comprehensive Cancer Network (NCCN) Neuroblastoma Committee, The American Society of Clinical Oncology, The American Society of Hematology, and the Children’s Oncology Group. She has over 10 years of research experience.

Dr. Slatnick’s clinical interests include all solid tumors with a specific interest in neuroblastoma therapy. Her primary research focuses on supportive care practices in immunocompromised patients, with a particular interest in infectious complications and antimicrobial management in the oncology patient population.

Board Certification and Academic Information

Academic Departments Pediatrics -Assistant Professor (Clinical)
Academic Divisions Hematology/Oncology
Board Certification
American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
National Board of Medical Examiners

Education history

Undergraduate Major: Cell Biology and Neuroscience; Minors: Spanish Language, Psychology - Rutgers University B.S.
Other Training Study Abroad Spanish Curriculum - Universidad de Salamanca
Professional Medical Medicine - University of Texas Southwestern Medical School M.D.
Internship Pediatrics - University of Colorado School of Medicine Intern
Residency Pediatrics - University of Colorado School of Medicine Resident
Fellowship Pediatric Hematology-Oncology - University of Colorado School of Medicine Fellow
Graduate Training Clinical Sciences - University of Colorado Anschutz Medical Campus M.S.

Selected Publications

Journal Article

  1. Slatnick LR, Hoogstra D, Fisher BT, Wolf J, Orgel E, Nessle CN, Patel PA, Miller TP, Wilkes J, Dupuis LL, Goode E, Jackson K, Willis DN, Elgarten C, Aftandilian C, Thompson J, Alexander S, Beauchemin MP, Belsky JA, Hess J, Prudowsky ZD, Guinipero T, Rossoff J, Demedis J, Walsh AM, Richards R, Choi DK, Dvorak CC, Esbenshade A (2025). Prevention and Management of Infectious Complications in Pediatric Patients With Cancer: A Survey Assessment of Current Practices Across Children's Oncology Group Institutions. Pediatric blood & cancer, e31532.
  2. Slatnick LR, Cost C, Garrington T, Donaldson N, Macy M (2024). Central Nervous System Metastases in Pediatric Patients With Ewing Sarcoma. Journal of pediatric hematology/oncology, 46(2), e180-e183.
  3. De Castro GC, Slatnick LR, Shannon M, Zhao Z, Jackson K, Smith CM, Whitehurst D, Elliott C, Clark CC, Scott HF, Friedman DL, Demedis J, Esbenshade A (2024). Impact of Time-to-Antibiotic Delivery in Pediatric Patients With Cancer Presenting With Febrile Neutropenia. JCO oncology practice, 20(2), 228-238.
  4. Zhao Z, Patel PA, Slatnick L, Sitthi-Amorn A, Bielamowicz KJ, Nunez FA, Walsh AM, Hess J, Rossoff J, Elgarten C, Myers R, Saab R, Basbous M, Mccormick M, Aftandilian C, Richards R, Nessle CN, Tribble AC, Sheth Bhutada JK, Coven SL, Runco D, Wilkes J, Gurunathan A, Guinipero T, Belsky JA, Lee K, Wong V, Malhotra M, Armstrong A, Jerkins LP, Cross SJ, Fisher L, Stein MT, Wu NL, Yi T, Orgel E, Haeusler GM, Wolf J, Demedis JM, Miller TP, Esbenshade A (2024). Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer. Journal of clinical oncology, 42(7), 832-841.
  5. Slatnick LR, Miller K, Scott HF, Loi M, Esbenshade AJ, Franklin A, Lee-Sherick A (2022). Serum lactate is associated with increased illness severity in immunocompromised pediatric hematology oncology patients presenting to the emergency department with fever. Frontiers in oncology, 12, 990279.
  6. Slatnick LR, Jimeno A, Gore L, Macy ME (2021). Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. Drugs Today (Barc), 57(11), 677-688.
  7. Slatnick LR, Thornhill D, Deakyne Davies SJ, Ford JB, Scott HF, Manco-Johnson MJ, Warren BB (2020). Disseminated Intravascular Coagulation Is an Independent Predictor of Adverse Outcomes in Children in the Emergency Department with Suspected Sepsis. J Pediatr, 225, 198-206.e2.

Letter

  1. Slatnick LR, Angione K, Hartman (2023). Precursor B-cell acute lymphoblastic leukemia in a pediatric patient with Bainbridge-Ropers syndrome. Pediatric blood & cancer, 70(1), e29873.

Other

  1. Bagatell R, Park JR, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai AV, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang (2024). Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(6), 413-433.